TGTX
TGTX
NASDAQ · Biotechnology

Tg Therapeutics Inc

$58.11
+0.95 (+1.66%)
As of Sep 22, 9:53 PM ET ·
Financial Highlights (FY 2026)
Revenue
591.27M
Net Income
429.02M
Gross Margin
83.7%
Profit Margin
72.6%
Rev Growth
+504.9%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 591.27M 1.04B 1.08B 956.87M
Gross Profit 494.65M 701.79M 727.04M 646.94M
Operating Income 118.31M 118.01M 120.46M 122.04M
Net Income 429.02M 129.57M 136.18M 105.42M
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Rev Growth +504.9% +16.6% +24.3% +11.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.31B 908.15M 880.79M 975.86M
Total Equity 2.10B 2.79B 2.78B 2.56B
D/E Ratio 1.10 0.33 0.32 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 118.37M 169.61M 170.48M 149.89M
Free Cash Flow 110.01M 140.89M 136.27M